Health Condition 1: L80- Vitiligo
Conditions
Interventions
Intervention1: Group A: Atrilal (Oral and Topical): Study drug Atrilal (Tablets and Powder) will be prepared in a single batch, according to the standard method described in National Formulary of Una
Sponsors
Central Research Institute of Unani Medicine
Eligibility
Inclusion criteria
Inclusion criteria: Patients of any sex aged18-40 years Non-segmental vitiligo with chronicity of 6 months to 2 years Vitiligo involving more than equal to 2% body surface area (BSA) Patients with less than 5 new lesions in the last month Patients with less than 15 lesions in the last 3 months Patients who have not taken systemic treatment in the last 4 weeks Patients who have not taken topical treatment in the last 2 weeks
Exclusion criteria
Exclusion criteria: Patients aged less than 18 years or more than 40 years Segmental vitiligo/ lip-tip or universal vitiligo/ vitiligo with leucotrichia Non-Segmental vitiligo with chronicity of less than 6 months or more than 2 years History of photosensitivity/ photo exaggerated dermatoses Pregnant or Lactating Women Significant Pulmonary/ Cardiovascular/ Hepato-renal Dysfunction Known cases of Immunocompromised states (HIV/ AIDS, etc.)/ Malignancies (cutaneous or internal) Patients not willing to attend treatment schedule regularly Patients not having a suitable facility for sun exposure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vitiligo Area Severity Index (VASI) Vitiligo Disease Activity (VIDA) Score Global Assessment (PGA) on VAS Investigators Global Assessment (IGA) Photographic Assessment Timepoint: VASI at baseline, 4th week, 8th week, 12th week and end of the 16 week REST at baseline and end of the trial | — |
Secondary
| Measure | Time frame |
|---|---|
| Lab investigations (Hemogram, LFT, RFT, ECG, CXR, CUE,Timepoint: At baseline, and end of the 16th week | — |
Countries
India
Contacts
Public ContactMohammad Nawab
Central Research Institute of Unani Medicine
Outcome results
None listed